This review offers a practical, evidence-based framework for using corticosteroids in adult patients with severe pneumonia, acute respiratory distress syndrome (ARDS), and septic shock in the intensive care unit (ICU). The authors emphasize that corticosteroid therapy requires nuanced, syndrome-specific decision-making rather than a universal strategy. The manuscript synthesizes findings from major randomized trials and recent focused guidelines to produce bedside-oriented recommendations, algorithms, and monitoring tools.
The guide is written specifically for intensivists, pulmonologists, infectious disease specialists, and critical care pharmacists who manage critically ill adults with respiratory infections and shock. The content is intended to support real-time clinical decisions in the ICU, with practical tools such as algorithms, monitoring tables, and interaction checklists.
A central conceptual pillar of the review is critical illness-related corticosteroid insufficiency (CIRCI). The review summarizes CIRCI as a pathophysiologic entity relevant to patients with severe sepsis, septic shock, and other critical illnesses in which endogenous corticosteroid responses may be inadequate for the severity of physiologic stress. Understanding CIRCI informs indications for exogenous corticosteroid therapy, selection of agent, and duration of treatment. The abstract references contemporary reviews and mechanistic literature to frame clinical application.
Agent selection is presented as syndrome-specific and evidence-informed. The review integrates results from multiple high-profile randomized trials and meta-analyses to guide choice of corticosteroid and indication. Trials explicitly cited include CAPE COD, RECOVERY, DEXA-ARDS, APROCCHSS, and ADRENAL. In addition, the authors reference the 2024 SCCM/ESICM focused guidelines as a contemporary source for practice recommendations. The review highlights pathogen-specific distinctions: for example, benefit demonstrated in COVID-19 and systematic harm reported in influenza, which should influence clinical decisions.
A dedicated pillar of the review is precise guidance on dosing, routes of administration, and tapering practices tailored to specific ICU syndromes. The abstract indicates that the full article provides practical, syndrome-specific dosing recommendations and tapering strategies intended for bedside use. Where the abstract does not report specific numeric dosing regimens or stepwise taper protocols, the authors state these are addressed in the body of the review; exact doses and schedules are not detailed in the abstract.
The review emphasizes structured safety monitoring as an essential component of corticosteroid use in critical illness. Monitoring covers common and important steroid-associated adverse effects relevant to the ICU population. The authors report that monitoring tables are provided to standardize surveillance during therapy, although the abstract does not enumerate the specific monitoring thresholds or interval frequencies.
An explicit focus of the guide is identification and management of high-risk drug–drug interactions with corticosteroids in critically ill patients. The review includes checklists designed to support clinicians in recognizing interactions that may alter steroid metabolism, efficacy, or toxicity. The abstract indicates practical tools but does not list individual interacting drugs in the summary.
The authors call out immunocompromised patients as a distinct and challenging subgroup. Landmark trials largely excluded this population, so evidence is limited. The review dedicates a section to the unique considerations, risks, and clinical exceptions when treating immunocompromised hosts, acknowledging the lack of direct trial data for many of these patients.
The review offers a comparative analysis of efficacy among different corticosteroid agents used in critical illness, synthesizing trial data to inform agent selection across syndromes. The abstract notes this comparative approach but does not provide numeric effect sizes or head-to-head trial outcomes in the summary; those details are presented in the full text according to the authors.
To translate evidence into bedside practice, the authors present practical algorithms, structured monitoring tables, and interaction checklists. These tools are designed to be used in real time by ICU teams to guide initiation, titration, tapering, and surveillance. The abstract emphasizes the inclusion of these implementation aids as a key feature of the review.
In summary, corticosteroids remain cornerstone therapies for selected critically ill patients with severe pneumonia, ARDS, and septic shock, but optimal use requires tailored, syndrome-specific judgment. The review consolidates evidence from major trials and contemporary guideline statements to produce a bedside roadmap covering pathophysiology (CIRCI), agent selection, dosing and tapering, structured safety monitoring, drug–drug interaction management, and comparative efficacy. The abstract indicates that the full review contains the detailed dosing recommendations and monitoring parameters used to operationalize these principles; if specific numeric regimens are required they should be confirmed in the full article text.